1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 製品タイプ別スニペット
3.2. バッテリータイプ別
3.3. 刺激タイプ別スニペット
3.4. アプリケーション別スニペット
3.5. エンドユーザー別スニペット
3.6. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 神経および精神疾患の有病率の上昇
4.1.1.2. DBS技術の進歩
4.1.2. 阻害要因
4.1.2.1. DBSデバイスと手技に伴う高コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 特許分析
5.5. 規制分析
5.6. SWOT分析
5.7. 技術分析
5.8. アンメット・ニーズ
6. 製品タイプ別
6.1. 製品紹介
6.1.1. 製品タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（製品タイプ別
6.2. シングルチャンネルシステム
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. デュアルチャンネルシステム
7. バッテリータイプ別
7.1. はじめに
7.1.1. 電池タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（電池タイプ別
7.2. 充電式システム
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 非充電式システム
8. 刺激タイプ別
8.1. はじめに
8.1.1. 刺激タイプ別市場規模分析および前年比成長率分析(%)
8.1.2. 市場魅力度指数（刺激タイプ別
8.2. 刺激タイプ*別
8.2.1. 導入
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 電圧制御デバイス
9. アプリケーション別
9.1. 導入
9.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.1.2. 市場魅力度指数（用途別
9.2. 運動障害*市場
9.2.1. 序論
9.2.2. 市場規模分析と前年比成長率分析(%)
9.2.3. パーキンソン病
9.2.4. ジストニア
9.2.5. 本態性振戦
9.2.6. その他
9.3. 精神疾患
9.3.1. 強迫性障害（OCD）
9.3.2. うつ病
9.3.3. その他
9.4. てんかん
9.5. 慢性疼痛
9.6. アルツハイマー病
9.7. トゥレット症候群
9.8. その他
10. エンドユーザー別
10.1. はじめに
10.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
10.1.2. 市場魅力度指数、エンドユーザー別
10.2. 病院と診療所
10.2.1. はじめに
10.2.2. 市場規模分析と前年比成長率分析(%)
10.3. 神経センター
10.4. 外来外科センター
10.5. その他
11. 地域別
11.1. はじめに
11.1.1. 地域別市場規模分析および前年比成長率分析(%)
11.1.2. 市場魅力度指数、地域別
11.2. 北米
11.2.1. 序論
11.2.2. 主な地域別ダイナミクス
11.2.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
11.2.4. 市場規模分析および前年比成長率分析 (%)、バッテリータイプ別
11.2.5. 市場規模分析および前年比成長率分析 (%)、刺激タイプ別
11.2.6. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.2.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.2.8. 市場規模分析および前年比成長率分析(%)、国別
11.2.8.1. 米国
11.2.8.2. カナダ
11.2.8.3. メキシコ
11.3. ヨーロッパ
11.3.1. はじめに
11.3.2. 主な地域別動向
11.3.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
11.3.4. 市場規模分析および前年比成長率分析（%）：バッテリータイプ別
11.3.5. 市場規模分析および前年比成長率分析 (%)、刺激タイプ別
11.3.6. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.3.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.3.8. 市場規模分析および前年比成長率分析(%)、国別
11.3.8.1. ドイツ
11.3.8.2. イギリス
11.3.8.3. フランス
11.3.8.4. スペイン
11.3.8.5. イタリア
11.3.8.6. その他のヨーロッパ
11.4. 南米
11.4.1. はじめに
11.4.2. 地域別主要市場
11.4.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
11.4.4. 市場規模分析および前年比成長率分析（%）：バッテリータイプ別
11.4.5. 市場規模分析および前年比成長率分析 (%)、刺激タイプ別
11.4.6. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.4.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.4.8. 市場規模分析および前年比成長率分析(%)、国別
11.4.8.1. ブラジル
11.4.8.2. アルゼンチン
11.4.8.3. その他の南米諸国
11.5. アジア太平洋
11.5.1. はじめに
11.5.2. 主な地域別ダイナミクス
11.5.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
11.5.4. 市場規模分析および前年比成長率分析（%）：バッテリータイプ別
11.5.5. 市場規模分析および前年比成長率分析（%）：刺激タイプ別
11.5.6. 市場規模分析および前年比成長率分析（%）, アプリケーション別
11.5.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
11.5.8. 市場規模分析および前年比成長率分析(%)、国別
11.5.8.1. 中国
11.5.8.2. インド
11.5.8.3. 日本
11.5.8.4. 韓国
11.5.8.5. その他のアジア太平洋地域
11.6. 中東・アフリカ
11.6.1. 序論
11.6.2. 主な地域別ダイナミクス
11.6.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
11.6.4. 市場規模分析および前年比成長率分析（%）：バッテリータイプ別
11.6.5. 市場規模分析および前年比成長率分析 (%)、刺激タイプ別
11.6.6. 市場規模分析および前年比成長率分析 (%)、用途別
11.6.7. 市場規模分析および前年比成長率分析 (%)、エンドユーザー別
12. 競合情勢
12.1. 競争シナリオ
12.2. 市場ポジショニング／シェア分析
12.3. M&A分析
13. 企業プロフィール
13.1. Medtronic plc*
13.1.1. 会社概要
13.1.2. 製品ポートフォリオと内容
13.1.3. 財務概要
13.1.4. 主な展開
13.2. Boston Scientific Corporation
13.3. Abbott Laboratories
13.4. Aleva Neurotherapeutics
13.5. NeuroPace, Inc.
13.6. SceneRay Co., Ltd.
13.7. PINS Medical
13.8. Renishaw plc.
13.9. BrainsWay Ltd.
13.10. inomed Medizintechnik GmbH
リストは網羅的ではありません
14. 付録
14.1. 会社概要とサービス
14.2. お問い合わせ
The global deep brain stimulation market reached US$ 800.12 million in 2023 and is expected to reach US$ 1,585.24 million by 2031 growing with a CAGR of 9.1% during the forecast period 2024-2031.
Deep Brain Stimulation (DBS) is a neurosurgical treatment that involves implanting electrodes in specific areas of the brain to modulate abnormal brain activity. The electrodes, connected to a pulse generator implanted in the chest, deliver controlled electrical impulses to targeted brain regions, altering neural activity in ways that can relieve symptoms of various neurological and psychiatric disorders.
The demand for deep brain stimulation is continuously boosting, which further fueling the market growth. For instance, according to the National Institute of Health (NIH), over 160,000 patients worldwide have undergone DBS for a variety of neurological and non-neurological conditions, with numbers increasing each year. As a clinical tool, DBS offers several advantages over other surgical approaches for neuromodulation.
Market Dynamics: Drivers
Rising prevalence of neurological and psychiatric disorders
The rising prevalence of neurological and psychiatric disorders is expected to drive the deep brain stimulation market, as the demand for effective treatments increases in line with global health trends. Neurological conditions such as Parkinson's disease, essential tremor and dystonia, as well as psychiatric disorders like obsessive-compulsive disorder (OCD) and depression, affect millions of people worldwide. DBS offers a viable and often life-changing alternative by directly modulating brain activity to alleviate symptoms.
For instance, according to the World Health Organization (WHO), in 2021, more than 3 billion people worldwide were living with a neurological condition. Over 80% of neurological deaths and health loss occur in low- and middle-income countries. This high prevalence is a significant driver for DBS use, as patients and providers increasingly seek effective, low-risk surgical options. Thus, the demand for deep brain stimulation is continuously increasing.
For psychiatric conditions like OCD and depression, the lack of effective treatment options for resistant cases is a major driver for DBS. According to the Regents of the University of California, Some 30% to 40% of patients do not respond to medications for depression and obsessive-compulsive disorder (OCD), creating a substantial demand for alternative treatments. DBS is positioned to meet this demand as an evidence-backed, surgical option with long-term benefits.
Moreover, in psychiatric disorders, deep brain stimulation typically targets specific areas of the brain that are involved in mood regulation and emotional processing. Common targets include the subthalamic nucleus, ventral capsule and anterior cingulate cortex. These regions are implicated in conditions like depression, obsessive-compulsive disorder (OCD) and generalized anxiety disorder.
For instance, the World Health Organization estimates that 1 in every 8 people in the world lives with a psychiatric disorder, with a 13% rise in psychiatric disorders and substance use seen in just the past decade. In the United States, the Centers for Disease Control and Prevention estimates that more than 1 in 5 adults lives with a psychiatric disorder. This increasing prevalence of psychiatric disorders boosting the demand for deep brain stimulation.
Restraints
Factors such as the high cost of DBS devices and procedures, the complexity and risks of surgical procedures, limited clinical evidence for emerging indications, challenges in post-implantation management and follow-up and technical limitations and device longevity issues are expected to hamper the deep brain stimulation market.
The high cost of deep brain stimulation devices and procedures is a significant factor that hampers market growth by limiting access and affordability for a large segment of potential patients. This financial barrier affects adoption rates, particularly in low- and middle-income regions and impacts both healthcare providers and patients.
For instance, according to the National Institute of Health, 2024, the inflation and currency-adjusted mean cost of the DBS device was USD 21,496.07 ± USD 8,944.16, the cost of surgery alone was USD 14,685.22 ± USD 8,479.66, the total cost of surgery was USD 40,942.85 ± USD 17,987.43 and the total cost of treatment until 1 year of follow-up was USD 47,632.27 ± USD 23,067.08.
Given the high costs, some patients may opt for less effective but more affordable treatments, even if they do not provide the same symptom relief as deep brain stimulation. Non-surgical options, such as medication, physical therapy or non-invasive brain stimulation techniques are generally much less expensive than DBS. This preference for more affordable alternatives further constrains the DBS market, particularly among those who prioritize cost over treatment efficacy.
Segment Analysis
The global deep brain stimulation market is segmented based on product type, battery type, stimulation type, application, end-user and region.
The movement disorders from the application segment accounted for approximately XX% of the global deep brain stimulation market share
The movement disorders segment is expected to hold the largest market share over the forecast period. Deep brain stimulation is particularly effective in managing symptoms associated with conditions like Parkinson's disease, essential tremor and dystonia, where it has become an established treatment option due to its ability to provide significant, sustained symptom relief. These effective benefits associated with deep brain stimulation for movement disorders encourage manufacturers to launch DBS systems with advanced features.
For instance, in January 2024, Abbott received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC deep brain stimulation system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders. The Liberta RC DBS system also requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.
Parkinson's disease is one of the most prevalent movement disorders, affecting more than 10 million people worldwide, with approximately 90,000 new cases diagnosed each year in the United States alone, according to the Parkinson's Foundation. The prevalence is anticipated to rise significantly as the global population ages. This large and growing patient base has made Parkinson's disease the primary condition treated with deep brain stimulation.
Moreover, movement disorders like Parkinson's disease, essential tremor and dystonia are initially managed with medications, such as levodopa for Parkinson’s or beta-blockers for essential tremor. However, these treatments often lose efficacy over time or cause significant side effects. For example, long-term levodopa use in Parkinson's disease can lead to motor complications such as dyskinesias. Deep brain stimulation provides a direct way to modulate brain circuits associated with movement control, offering an effective, less side-effect-prone alternative for patients who have exhausted medication options.
Deep brain stimulation has a strong body of clinical evidence supporting its efficacy and safety for movement disorders, leading to regulatory approvals that drive market growth. The FDA first approved DBS for essential tremor in 1997, followed by approvals for Parkinson’s disease and dystonia, solidifying its role as a core therapy for these conditions. Many studies have demonstrated the long-term benefits of DBS for Parkinson’s disease, with improvements in motor function and quality of life lasting for years.
Geographical Analysis
North America accounted for approximately XX% of the global deep brain stimulation market share
North America region is expected to hold the largest market share over the forecast period owing to the technological advancements and high rate of adoption of deep brain stimulation devices and procedures. For instance, according to Orlando Neurosurgery, approximately 12,000 DBS procedures occur in the United States each year.
North American companies are at the forefront of introducing next-generation DBS devices that offer improved efficacy and patient comfort. Innovations such as rechargeable batteries, remote programming and adaptive deep brain stimulation are gaining traction and are widely adopted in the region, especially in the United States. These advancements not only improve patient outcomes but also make deep brain stimulation more appealing to a broader patient base.
For instance, in January 2021, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System. The portfolio, approved for conditional use in a magnetic resonance imaging (MRI) environment, consists of a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators (IPGs) that power Cartesia Directional Leads, designed to provide optimal symptom relief.
There is a rising prevalence of various movement and psychiatric disorders in North America, especially in the United States, further increasing the demand for deep brain stimulation devices and procedures in the region. For instance, according to the Parkinson's Foundation, nearly one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Nearly 90,000 people in the U.S. are diagnosed with PD each year.
Market Segmentation
By Product Type
• Single-Channel Systems
• Dual-Channel Systems
By Battery Type
• Rechargeable Systems
• Non-Rechargeable Systems
By Stimulation Type
• Constant Current Devices
• Voltage-Controlled Devices
By Application
• Movement Disorders
o Parkinson's Disease
o Dystonia
o Essential Tremor
o Others
• Psychiatric Disorders
o Obsessive-Compulsive Disorder (OCD)
o Depression
o Others
• Epilepsy
• Chronic Pain
• Alzheimer's Disease
• Tourette Syndrome
• Others
By End-User
• Hospitals and Clinics
• Neurological Centers
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the deep brain stimulation market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Aleva Neurotherapeutics, NeuroPace, Inc., SceneRay Co., Ltd., PINS Medical, Renishaw plc., BrainsWay Ltd., inomed Medizintechnik GmbH and among others.
Key Developments
In April 2024, Medtronic India launched its NeuroSmartTM Portable Micro Electrode Recording (MER) Navigation system for Deep brain stimulation (DBS) to treat Parkinson’s disease. The NeuroSmartTM Portable MER Navigation system, developed by Alpha Omega Engineering, features advanced neurophysiological navigation mapping and enables accurate electrode placement while recording neural activity. Its advanced capabilities for enhanced target localization, based on HaGuide automatic navigation, help identify the most effective target for the patient, ensuring optimum symptom relief.
In August 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) approval for Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s and people with essential tremors. Medtronic is the first and only company to receive FDA approval to offer DBS surgery while a patient is asleep (under general anesthesia) or awake.
In September 2024, Abbott launched a pivotal clinical trial to see if its deep brain stimulation approach can make headway against treatment-resistant depression. The company previously collected green lights for brain neuromodulation systems that help treat the movement symptoms that come with Parkinson’s disease and essential tremor, as well as for implants that focus on the spinal cord to aid in cases of chronic pain. The devices send small electrical pulses to spur tissue activity, not unlike a pacemaker.
Why Purchase the Report?
• To visualize the global deep brain stimulation market segmentation based on product type, battery type, stimulation type, application, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the deep brain stimulation market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global deep brain stimulation market report would provide approximately 78 tables, 74 figures and 189 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Battery Type
3.3. Snippet by Stimulation Type
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Neurological and Psychiatric Disorders
4.1.1.2. Rising Advancements in DBS Technology
4.1.2. Restraints
4.1.2.1. High Cost Associated with DBS Devices and Procedures
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Technological Analysis
5.8. Unmet Needs
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Single-Channel Systems*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Dual-Channel Systems
7. By Battery Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
7.1.2. Market Attractiveness Index, By Battery Type
7.2. Rechargeable Systems*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Rechargeable Systems
8. By Stimulation Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
8.1.2. Market Attractiveness Index, By Stimulation Type
8.2. Stimulation Type*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Voltage-Controlled Devices
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Movement Disorders*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Parkinson's Disease
9.2.4. Dystonia
9.2.5. Essential Tremor
9.2.6. Others
9.3. Psychiatric Disorders
9.3.1. Obsessive-Compulsive Disorder (OCD)
9.3.2. Depression
9.3.3. Others
9.4. Epilepsy
9.5. Chronic Pain
9.6. Alzheimer's Disease
9.7. Tourette Syndrome
9.8. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals and Clinics*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Neurological Centers
10.4. Ambulatory Surgical Centers
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. U.K.
11.3.8.3. France
11.3.8.4. Spain
11.3.8.5. Italy
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Battery Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stimulation Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Medtronic plc*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Boston Scientific Corporation
13.3. Abbott Laboratories
13.4. Aleva Neurotherapeutics
13.5. NeuroPace, Inc.
13.6. SceneRay Co., Ltd.
13.7. PINS Medical
13.8. Renishaw plc.
13.9. BrainsWay Ltd.
13.10. inomed Medizintechnik GmbH
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us
❖ 世界の脳深部刺激療法市場に関するよくある質問(FAQ) ❖
・脳深部刺激療法の世界市場規模は？
→DataM Intelligence社は2023年の脳深部刺激療法の世界市場規模を8億1012万米ドルと推定しています。
・脳深部刺激療法の世界市場予測は？
→DataM Intelligence社は2031年の脳深部刺激療法の世界市場規模を15億8524万米ドルと予測しています。
・脳深部刺激療法市場の成長率は？
→DataM Intelligence社は脳深部刺激療法の世界市場が2024年～2031年に年平均9.1%成長すると予測しています。
・世界の脳深部刺激療法市場における主要企業は？
→DataM Intelligence社は「Medtronic plc、Boston Scientific Corporation、Abbott Laboratories、Aleva Neurotherapeutics、NeuroPace, Inc.、SceneRay Co.Ltd.、PINS Medical、Renishaw plc.、BrainsWay Ltd.、inomed Medizintechnik GmbHなど ...」をグローバル脳深部刺激療法市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
